PODCAST INTERVIEWS

medwireNews goes behind the headlines, talking to researchers and independent experts about how the latest findings will impact clinicians caring for children with endocrine disorders.

Also available to listen on...
In our latest podcast, Specialist nurse and educator Kate Davies asks clinical psychologist Julie Alderson about the optimal integration of psychology into a differences in sexual development clinical service.
In our latest podcast, Professor Sadaf Farooqi discusses the most recent findings from the Genetics Of Obesity Study, and what they mean for families and children with severe early-onset obesity.
Our podcast features Dr Salvatore Vaccarella, from the International Agency for Research on Cancer in Lyon, France, lead author of a recent article in The Lancet Diabetes & Endocrinology indicating that thyroid cancer overdiagnosis is a concern for children and adolescents.
Dr Cheri Deal discusses the use of growth hormone in children with Prader-Willi syndrome, the importance of multidisciplinary care and the future of treatment for this genetic condition.
Our podcast with consortium member, Stefano Cianfarani, from the University of Rome Tor Vergata, Italy, discusses the safety of growth hormone.
Our podcast with Dr Sogol Mostoufi, from the Children’s Hospital of Philadelphia in Pennsylvania, USA, focuses on the treatment-related endocrine side effects commonly experienced by childhood cancer survivors, and the need for screening, life-long follow-up and treatment in this high-risk population.
Professor Ravi Savarirayan talks through the recently published results in The New England Journal of Medicine for the C-type natriuretic peptide analogue vosoritide in children with achondroplasia.
In this podcast, Dr Shylaja Srinivasan discusses the care of children and adolescents with type 2 diabetes, and how the findings of the TODAY2 and Ellipse trials will inform treatment decisions.
In our first edition, Professor Frederic Castinetti discussing the results of an international collaboration to study the natural history and treatment outcomes of multiple endocrine neoplasia type 2B, and Professor Martin Savage comments on a randomized trial of letrozole versus testosterone in boys with constitutional delay of growth and puberty.
Martin Savage
Programme Director

Sign up for eAlerts

Be the first to hear about new resources and content by signing up to receive our eAlerts.

Please provide your details:

Follow us
This programme is made possible thanks to an educational grant received from Merck Healthcare KGaA, Darmstadt, Germany.
medwireNews is an independent clinical news service provided by Springer Healthcare Limited. © 2022 Springer Healthcare is part of the Springer Nature Group